BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:F182112 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of F182112\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07828522-3212@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:F182112: Phase 2 readout est. (NCT07828522)
DESCRIPTION:F182112\, phase 2\, Multiple Myeloma.\nStudy: F182112 in Combin
 ation With Isatuximab and Lenalidomide for the Treatment of Patients With 
 Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 9 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/f182112#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07828522
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829614-3212@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:F182112: Phase 1 readout est. (NCT07829614)
DESCRIPTION:F182112\, phase 1.\nStudy: F182112 Phase Ib Clinical Study for 
 the Treatment of Patients With Systemic Lupus Erythematosus\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/f182112#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07829614
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816341-3212@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:F182112: Phase 1 readout est. (NCT07816341)
DESCRIPTION:F182112\, phase 1.\nStudy: F182112 in Relapsed/Refractory Autoi
 mmune Hemolytic Anemia\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/f182112#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07816341
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07312188-3212@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20280520
DTEND;VALUE=DATE:20280521
SUMMARY:F182112: Phase 2 readout est. (NCT07312188)
DESCRIPTION:F182112\, phase 2\, Multiple Myeloma.\nStudy: A Study of F18211
 2 in the Treatment of Patients With Relapsed or Refractory Multiple Myelom
 a\nEstimated primary completion: 20 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/f182112#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07312188
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579234-3212@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20290125
DTEND;VALUE=DATE:20290126
SUMMARY:F182112: Phase 3 readout est. (NCT07579234)
DESCRIPTION:F182112\, phase 3\, Multiple Myeloma.\nStudy: A Multicenter\, R
 andomized\, Open-label\, Parallel-group\, Controlled\, Superiority Phase I
 II Clinical Study Comparing the Efficacy and Safety of F182112 Versus Stan
 dard of Care in Patients With Relapsed or Refractory Multiple Myeloma\nEst
 imated primary completion: 25 January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/f182112#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07579234
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
